203 related articles for article (PubMed ID: 35344648)
1. Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI.
Kim HR; Jo H; Kim H; Hong J; Park S; Jung HA; Lee SH; Ahn JS; Ahn MJ
Cancer Res Treat; 2023 Jan; 55(1):344-349. PubMed ID: 35344648
[TBL] [Abstract][Full Text] [Related]
2. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Kogure Y; Tachihara M; Fujimoto D; Yamaguchi K; Hamaguchi N; Okamoto I; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2021 Jul; 22(4):376-380. PubMed ID: 33612406
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
Wang M; Zhu F; Luo N; Li M; Qi Y; Wang M
Medicine (Baltimore); 2021 Nov; 100(44):e27727. PubMed ID: 34871271
[TBL] [Abstract][Full Text] [Related]
7. Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.
Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
J Cancer Res Clin Oncol; 2023 Jan; 149(1):5-14. PubMed ID: 36318332
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases.
Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.
Wu H; Zhang Q; Zhai W; Chen Y; Yang Y; Xie M; Huang Z; Xu Y; Li H; Gong L; Yu S; Fan Y; Chen K
Lung Cancer; 2024 Feb; 188():107475. PubMed ID: 38266613
[TBL] [Abstract][Full Text] [Related]
10. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
Miyawaki T; Kenmotsu H; Yabe M; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Deguchi S; Mitsuya K; Naito T; Murakami H; Mori K; Harada H; Hayashi N; Takahashi K; Takahashi T
Invest New Drugs; 2021 Dec; 39(6):1732-1741. PubMed ID: 34259953
[TBL] [Abstract][Full Text] [Related]
11. Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.
Nanjo S; Hata A; Okuda C; Kaji R; Okada H; Tamura D; Irie K; Okada H; Fukushima S; Katakami N
Br J Cancer; 2018 Jan; 118(1):32-37. PubMed ID: 29190637
[TBL] [Abstract][Full Text] [Related]
12. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status.
Liao J; Huang Y; Gan J; Pang L; Ali WAS; Yang Y; Chen L; Zhang L; Fang W
Cancer Control; 2022; 29():10732748221081360. PubMed ID: 35201951
[TBL] [Abstract][Full Text] [Related]
14. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
[No Abstract] [Full Text] [Related]
15. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
[TBL] [Abstract][Full Text] [Related]
16. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B
J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
Yang JCH; Kim SW; Kim DW; Lee JS; Cho BC; Ahn JS; Lee DH; Kim TM; Goldman JW; Natale RB; Brown AP; Collins B; Chmielecki J; Vishwanathan K; Mendoza-Naranjo A; Ahn MJ
J Clin Oncol; 2020 Feb; 38(6):538-547. PubMed ID: 31809241
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
[TBL] [Abstract][Full Text] [Related]
19. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Liu J; Jin B; Su H; Qu X; Liu Y
BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
[TBL] [Abstract][Full Text] [Related]
20.
Nanjo S; Arai S; Wang W; Takeuchi S; Yamada T; Hata A; Katakami N; Okada Y; Yano S
Mol Cancer Ther; 2017 Mar; 16(3):506-515. PubMed ID: 28138027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
